Microbial metabolite therapy for progressive multiple sclerosis
University of Toronto researchers have identified a microbiome-derived metabolite linked to age-related cortical grey matter demyelination in progressive MS. The team is validating this metabolite therapeutically and screening for additional candidates to develop treatments for progressive forms of multiple sclerosis.
Overview
This research program targets progressive multiple sclerosis (MS), a form of the disease that does not respond to existing immunomodulatory therapies. The team at the University of Toronto has discovered that age-related changes in the gut microbiome contribute to cortical grey matter demyelination and neurodegeneration, which drive progressive disability in MS patients. By identifying specific microbial-derived metabolites associated with these changes, the program aims to develop new therapeutic candidates that can prevent or slow cortical grey matter atrophy and disease progression.
The opportunity centers on a metabolite that is differentially abundant in animals receiving microbiota from young donors versus aged donors. Supplementation of this metabolite attenuated MS-like disease in preclinical models, suggesting a path toward both therapeutic and prophylactic interventions for progressive MS.
Technical specifications
Research platform and approach:
- A validated mouse model of MS that exhibits sustained demyelination and neurodegeneration in cortical grey matter with age
- Xenotransplantation of microbiota from aged versus young human donors to study age-dependent microbiome effects on disease
- Metabolite profiling to identify differentially abundant microbial metabolites linked to grey matter pathology
- In vivo testing of candidate metabolites for therapeutic and prophylactic efficacy in reducing cortical demyelination
- A discovery pipeline designed to identify additional novel metabolites with neuroprotective potential
Key findings to date:
- Aged human donor microbiota accelerates grey matter demyelination compared to young donor microbiota
- A specific metabolite absent in the aged-microbiota group was linked to reduced demyelination
- Metabolite supplementation in the aged-microbiota group attenuated MS-like disease in pilot experiments
Technology readiness level
The program is at an early-to-mid preclinical stage. A lead metabolite candidate has been identified and shown efficacy in a pilot animal study. The research team is now advancing validation in two directions: confirming the lead metabolite's therapeutic and prophylactic potential in established preclinical models, and screening the experimental pipeline for additional novel metabolites. Further work in dose optimization, pharmacokinetics, and eventual clinical translation would be required before human studies.
About University of Toronto
The University of Toronto is a comprehensive public research university with three campuses in the Toronto region and a globally scaled research enterprise. Its downtown footprint is embedded within a major academic health network and an adjacent innovation district, enabling co-located labs, clinical trials, and rapid testing with end users. Companies connect through co-op and long-duration internships, sponsored research, and access to shared core facilities and prototyping resources. Research is supported by Canada’s Tri‑Agency (NSERC, CIHR, SSHRC) and the Canada Foundation for Innovation, alongside provincial programs and industry partnerships. A dedicated technology transfer office provides IP management, licensing, and startup support through a coordinated entrepreneurship network.
delivered to your inbox.